About 100 reports

  • Risk Factors for Ovarian Cancer
  • PLATINUM-RESISTANT OVARIAN CANCER

The ACS estimates that the lifetime risk of developing ovarian cancer is ## in ## and the lifetime risk of dying from ovarian cancer is ## in ## (ACS, 2018).

  • Ovarian Cancer
  • United States
  • Forecast
  • AstraZeneca PLC
  • Roche Group

Thus, the increase in the incidence of ovarian cancer is expected to drive the growth of the global ovarian cancer drugs market during the forecast period.

  • Cancer
  • Ovarian Cancer
  • World
  • Forecast
  • RISK FACTORS FOR OVARIAN CANCER
  • 2 Ovarian Cancer: Executive Summary

THE ACS ESTIMATES THAT THE LIFETIME RISK OF DEVELOPING OVARIAN CANCER IS ## IN ## AND THE LIFETIME RISK OF DYING FROM OVARIAN CANCER IS ## IN ## (ACS, 2018).

  • Ovarian Cancer
  • Japan
  • United States
  • World
  • Forecast

GLOBAL OVARIAN CANCER DRUGS MARKET: ##IRESEARCH MARKET SHARE ANALYSIS List of Tables TABLE ##.

  • Ovarian Cancer
  • Therapy
  • United States
  • World
  • Market Size

Business Overview Products and Services Immuno-Oncology Platform List of Tables Summary Table A : Global Ovarian Cancer Therapeutic Market, by Cancer Type, Through 2022 Summary Table B : Global Ovarian Cancer Therapeutic Market, by Region, Through 2022 Ta

  • Cancer
  • Ovarian Cancer
  • Therapy
  • World
  • Market Size

Chemotherapy ## Figure ##: XMT-## for Ovarian Cancer (June ##, 2019): Phase Ib - First-in-Human (NaPi##b) ## Figure ##: Tivopath (Oncology) for Ovarian Cancer (June ##, 2019): Phase II - TIVO (Ovarian Cancer) ## Figure ##: Mirvet

  • Cancer
  • Oncology
  • Ovarian Cancer
  • Pathology
  • Therapy

Ovarian Cancer KOL Interview – US, East Coast A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for ovarian cancer.

  • Cancer
  • Ovarian Cancer
  • United States
  • Market Size

UNITED STATES OVARIAN CANCER DRUGS MARKET: ##IRESEARCH MARKET SHARE ANALYSIS List of Tables TABLE ##.

  • Ovarian Cancer
  • Therapy
  • United States
  • Forecast

Ovarian Cancer Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class, By Major Markets And Segment Forecasts, 2016 - 2022 Chapter ## Research Methodology ##. ##.

  • Ovarian Cancer
  • Therapy
  • United States
  • Forecast
  • Ovarian cancer gene therapy molecules by type of ovarian cancer
  • ANALYSIS BY TYPE OF OVARIAN CANCER

Gene therapy is emerging as one of the most exciting approaches for the treatment of ovarian cancer.

  • Ovarian Cancer
  • United States
  • Advantagene, Inc.
  • Celsion Corporation
  • Takara Bio Inc.

Ovarian Cancer: Update Bulletin [January 2018] This edition presents key opinion leader (KOL) views on recent developments in the ovarian cancer market.

  • Ovarian Cancer
  • Targeted Therapy
  • Therapy
  • United States
  • Market Competition
  • 2.5 EPIDEMIOLOGICAL FORECAST FOR OVARIAN CANCER (2015-2025)
  • 2.5.3 Age-Standardized Diagnosed Incidence of Ovarian Cancer

Cancer; ##(##): ##-##.

  • Ovarian Cancer
  • Japan
  • United States
  • World
  • Forecast

Ovarian Cancer Disease Coverage Forecast and Market Analysis to 2023 CONTENTS ## FORECAST: OVARIAN CANCER (Published on ## August 2017) ## OVERVIEW ## EXECUTIVE SUMMARY ## MARKET OVERVIEW AND TRENDS ## MARKET DEFINITION AND METHODOLOGY ## AVASTIN (BEVACIZUMA

  • Ovarian Cancer
  • European Union
  • Japan
  • United States
  • Demand

& nbsp; Most payers however will wait for the ovarian cancer market to mature before they deploy any contracts for preferred products.

  • Ovarian Cancer
  • Therapy
  • European Union
  • United States

Global Ovarian Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Ovarian Cancer
  • France
  • United States
  • World
  • Forecast

Estrogen signaling is involved in a number of diseases with big market indications such as breast cancer, prostate cancer and osteoporosis.

  • Ovarian Cancer
  • China
  • Demand
  • Bayer Schering Pharmaceutical Co., Ltd
  • Roche Group
  • Ovarian Cancer Treatment Drugs Sales Volume (million yuan)
  • CHAPTER IV OVARIAN CANCER TREATMENT DRUGS PRODUCTION AND DEMAND

Ovarian cancer is the fifth leading cause of death from cancer in women and the leading cause of death from gynecological cancer.

  • Ovarian Cancer
  • China
  • Demand
  • Bayer Schering Pharmaceutical Co., Ltd
  • Roche Group
  • BIOMARKERS USED IN OVARIAN CANCER (2017)
  • THE U.S. OVARIAN CANCER INCIDENCE FORECAST (2017-2025)

The genetic factor is one of the reasons for the risk of ovarian and also for breast cancer within the family.

  • Ovarian Cancer
  • World
  • AbbVie Inc.
  • AstraZeneca PLC
  • Clovis Oncology, Inc.

Europe Ovarian Cancer Epidemiology and Patient Flow Analysis - 2017 ##.

  • Ovarian Cancer
  • Europe
  • France
  • Germany
  • Forecast
  • Ovarian Cancer Treatment Drugs Sales Volume (million yuan)
  • CHAPTER IV OVARIAN CANCER TREATMENT DRUGS PRODUCTION AND DEMAND

Ovarian cancer is the fifth leading cause of death from cancer in women and the leading cause of death from gynecological cancer.

  • Ovarian Cancer
  • China
  • ACON Biotech Co., Ltd
  • Bayer Schering Pharmaceutical Co., Ltd
  • Ltd Jiangsu Hengrui Medicine Co.

Ovarian cancer Phase ## Clinical Trials, 2016 ##.

  • Ovarian Cancer
  • France
  • Germany
  • United States
  • Market Size
  • Launch of Lynparza for ovarian cancer
  • EPIDEMIOLOGY - OVARIAN CANCER

The greatest emphasis is being placed on combinations with PD-##/ PD-L## inhibitors in breast cancer, as well as combinations with chemotherapy in ovarian, breast, prostate, and other cancers.

  • Ovarian Cancer
  • Targeted Therapy
  • United States
  • AbbVie Inc.
  • Pfizer Inc.

Nov ##, 2019: ORYX confirms ParvOryx mode of action in tumor explant model Nov ##, 2019: NextCure Presents Updated Clinical Data from NC## Phase ##/ ## Clinical Trial at the ##th Annual Meeting of Society for Immunotherapy of Cancer (SITC) and Announces Initiation of Phase ## Por

  • Clinical Trial
  • Ovarian Cancer
  • Pharmaceutical
  • Therapy
  • World

Drug Overview: Rubraca

8770 10000 7800

Drug Overview: Rubraca TABLE OF CONTENTS ## Product Profiles ## Rubraca : Prostate cancer ## Rubraca : Ovarian cancer LIST OF FIGURES ## Figure ##: Rubraca for prostate cancer – SWOT analysis ## Figure ##: Datamonitor Healthcare’s drug assessment summary of R

  • Ovarian Cancer
  • Prostate Cancer
  • European Union
  • United States
  • Market Description

Drug Analysis: Rubraca

8770 10000 7800

Drug Analysis: Rubraca Product Profiles Rubraca : Prostate cancer Rubraca : Ovarian cancer LIST OF FIGURES Figure ##: Rubraca for prostate cancer – SWOT analysis Figure ##: Datamonitor Healthcare’s drug assessment summary of Rubraca for prostate

  • Ovarian Cancer
  • Prostate Cancer
  • Therapy
  • European Union
  • United States

Ovarian cancer Phase ## Clinical Trials, 2016 ##.

  • Ovarian Cancer
  • France
  • Germany
  • Italy
  • Market Size

Ovarian cancer Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Ovarian Cancer
  • Pathology
  • Japan
  • Market Size

Ovarian cancer Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Ovarian Cancer
  • Pathology
  • United States
  • Market Size

Ovarian cancer Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Ovarian Cancer
  • Pathology
  • United Kingdom
  • Market Size

Ovarian cancer Phase ## Clinical Trials, 2016 ##.

  • Cancer
  • Ovarian Cancer
  • Pathology
  • Italy
  • Market Size